Fig. 2

MVs mediate GLS1 release in HIV-1-infected MDM and immune-activated microglia. a At 7 days post-infection, mock-infected and HIV-1 infected MDM were treated with GW4869 for 24 h in serum-free media. MVs were isolated from the supernatants and MV protein lysates were prepared. The levels of Alix, flotillin-2, and GAC were determined by Western blots. b, c, d Densitometric quantifications of the Alix (b), flotillin-2 (c), and GAC (d) protein levels were presented as fold change relative to the mock-infected controls. e MVs were isolated from the supernatants of control and LPS-treated microglia in the presence and absence of GW4869. MV lysates were subjected to Alix, flotillin-2, and GAC detection through Western blots. Results shown are representative of three independent experiments. f, g, h Densitometric quantifications of the Alix (f), flotillin-2 (g), and GAC (h) protein levels were presented as fold change relative to the untreated controls. DMSO was used as solvent control for GW4869. Western blot results shown are representative of three independent experiments. Quantification results shown are means ± SD of experiments performed in triplicate (n = 3 donors). ** and *** denotes p < 0.01 and 0.001 in comparison to mock-infected or untreated control; #, ## and ### denote p < 0.05, 0.01 and 0.001 in comparison to HIV-infected or immune-activated groups, respectively